LLY
Eli Lilly and Company
Price performance
Sep 18, 2026About
Company activity
26 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/05 | LLY | 8-K | Eli Lilly Reports Strong Q2 2026 Financial Results and Raises Full-Year Guidance | — | — | — |
| 05/20 | LLY | 8-K | Eli Lilly Completes Offering of Multiple Series of Notes | — | — | — |
| 05/07 | LLY | 8-K | Eli Lilly Shareholders Elect Directors at 2026 Annual Meeting | — | — | — |
| 04/30 | LLY | 8-K | Eli Lilly Announces Q1 2026 Financial Results | — | — | — |
| 02/04 | LLY | 8-K | Eli Lilly Announces Strong Q4 2025 Results and 2026 Guidance | — | — | — |
| 11/21/25 | LLY | 8-K | Eli Lilly Appoints Dr. Carolyn R. Bertozzi to Board of Directors | — | — | — |
| 10/30/25 | LLY | 8-K | Eli Lilly Reports Strong Q3 2025 Results with 54% Revenue Growth and Raised Guidance | — | — | — |
| 08/20/25 | LLY | 8-K | Eli Lilly Announces Issuance of Multiple Debt Notes | — | — | — |
| 08/07/25 | LLY | 8-K | Eli Lilly Announces Strong Second Quarter 2025 Results and Raises Full-Year Guidance | — | — | — |
| 05/08/25 | LLY | 8-K | Eli Lilly Shareholders Approve Director Elections and Executive Compensation at 2025 Annual Meeting | — | — | — |
| 05/01/25 | LLY | 8-K | Eli Lilly Q1 2025 Financial Results: Significant Revenue Growth and Pipeline Updates | — | — | — |
| 02/12/25 | LLY | 8-K | Eli Lilly Announces New Note Issuance | — | — | — |
| 02/06/25 | LLY | 8-K | Eli Lilly Reports Strong Q4 2024 Financial Results and Provides 2025 Guidance | — | — | — |
| 01/14/25 | LLY | 8-K | Eli Lilly Updates 2024 Revenue Guidance and Announces 2025 Outlook | — | — | — |
| 11/19/24 | LLY | 8-K | Eli Lilly Board Welcomes New Director and Announces Resignation | — | — | — |
| 10/30/24 | LLY | 8-K | Eli Lilly Reports Q3 2024 Financial Results with Strong Revenue Growth | — | — | — |
| 09/09/24 | LLY | 8-K | Eli Lilly Appoints Lucas Montarce as New CFO | — | — | — |
| 08/16/24 | LLY | 8-K | Eli Lilly Announces Retirement of Board Member Dr. Marschall S. Runge | — | — | — |
| 08/14/24 | LLY | 8-K | Eli Lilly Issues Bonds Worth $4.96 Billion | — | — | — |
| 08/08/24 | LLY | 8-K | Eli Lilly Q2 2024: Significant Revenue Growth and EPS Increase | — | — | — |
| 07/10/24 | LLY | 8-K | Eli Lilly Announces CFO Resignation and Interim Replacement | — | — | — |
| 06/05/24 | LLY | 8-K | Eli Lilly CFO Anat Ashkenazi Resigns to Pursue New Career | — | — | — |
| 05/09/24 | LLY | 8-K | Eli Lilly Shareholders Approve Director Elections and Executive Compensation at 2024 Annual Meeting | — | — | — |
| 04/30/24 | LLY | 8-K | Eli Lilly Reports Q1 2024 Financial Results and Raises Full-Year Revenue Guidance | — | — | — |
| 02/09/24 | LLY | 8-K | Eli Lilly Announces Underwriting Agreement for Note Issuance | — | — | — |
| 02/06/24 | LLY | 8-K | Eli Lilly Reports Strong Q4 2023 Financial Results and 2024 Guidance | — | — | — |
LLY filing record
Eli Lilly and Company (LLY): 26 8-K filings summarized, the most recent on Aug 5, 2026.
What the 8-K filings said
- Aug 5, 2026 · high impact
Eli Lilly and Company announced its financial results for the second quarter of 2026, reporting a 48% increase in revenue to $23.0 billion, driven by strong demand for Mounjaro and Zepbound. The company raised its full-year revenue guidance to a range of $85.0 billion to $87.0 billion and updated its non-GAAP EPS…
Eli Lilly Reports Strong Q2 2026 Financial Results and Raises Full-Year Guidance - May 20, 2026 · medium impact
On May 20, 2026, Eli Lilly and Company completed its offering of multiple series of notes, including floating rate and fixed rate notes, totaling approximately $8.94 billion in net proceeds. The notes were issued under an underwriting agreement and an indenture, with specific interest rates and redemption terms. The…
Eli Lilly Completes Offering of Multiple Series of Notes - May 7, 2026 · high impact
At the 2026 Annual Meeting held on May 4, 2026, Eli Lilly and Company shareholders elected four new directors to serve three-year terms. The meeting also saw approval of executive compensation and the ratification of Ernst & Young LLP as the independent auditor. However, several shareholder proposals, including…
Eli Lilly Shareholders Elect Directors at 2026 Annual Meeting - Apr 30, 2026 · low impact
Eli Lilly and Company announced its financial results for the quarter ended March 31, 2026. The report includes key financial metrics and operational highlights for the period. Further details can be found in the attached press release.
Eli Lilly Announces Q1 2026 Financial Results - Feb 4, 2026 · medium impact
Eli Lilly and Company reported a 43% increase in Q4 2025 revenue to $19.3 billion, driven by volume growth from Mounjaro and Zepbound. The company posted a 51% increase in reported EPS to $7.39 and a 42% increase in non-GAAP EPS to $7.54, inclusive of $0.52 of acquired IPR&D charges. Regulatory approvals for Kwikpen…
Eli Lilly Announces Strong Q4 2025 Results and 2026 Guidance
SEC filings in the last five years
- 42 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K